Supplementary_submission_PROGNOSTIC_ROLE_OF_PIK3CA_AND_TP53 – Supplemental material for Prognostic role of PIK3CA and TP53 in human papillomavirus–negative oropharyngeal cancers

<p>Supplemental material, Supplementary_submission_PROGNOSTIC_ROLE_OF_PIK3CA_AND_TP53 for Prognostic role of PIK3CA and TP53 in human papillomavirus–negative oropharyngeal cancers by Carlo Resteghini, Federica Perrone, Rosalba Miceli, Cristiana Bergamini, Salvatore Alfieri, Ester Orlandi, Marco Guzzo, Roberta Granata, Donata Galbiati, Stefano Cavalieri, Laura Locati, Lisa Licitra and Bossi Paolo in Tumori Journal</p

Flow-chart of patients population.

<p>Flow-chart of patients population.</p

ALK FISH examples.

<p>Gain of ALK GCN (including both low and high genomic gain) was defined as a mean of 3 to 5 fusion signals in ≥10% of cells (Figure on right). Disomic cells are shown in Figure on left.</p

Overall survival analysis.

<p>Kaplan-Meier curves for overall survival according to ALK status: increase of gene copy number vs. disomic status.</p

MOESM3 of GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

Additional file 3: Figure S2. Comparison of Kaplan-Meier curves for progression-free survival according to GNAS mutational status in both the prospective (metronomic capecitabine and bevacizumab) and the retrospective cohort (FOLFOX-4)

MOESM2 of GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

Additional file 2: Figure S1. Comparison of Kaplan-Meier curves for progression-free survival according to GNAS mutational status in the retrospective cohort (FOLFOX-4)